DESYREL (trazodone hydrochloride) by Pragma Bio is trazodone's antidepressant action is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the cns. Approved for depression. First approved in 1981.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
DESYREL (trazodone hydrochloride) is an oral tablet antidepressant approved in 1981 that treats major depression through dual serotonergic mechanisms: selective serotonin reuptake inhibition combined with 5HT2 receptor antagonism. The exact contribution of each mechanism to its antidepressant effect remains incompletely understood.
Product is in mature LOE-approaching phase with limited growth trajectory; brand team will focus on lifecycle management and generic transition planning.
trazodone's antidepressant action is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS. Trazodone is both a selective serotonin reuptake inhibitor (SSRI) and a 5HT2 receptor antagonist and the net result of this action on serotonergic…
PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese
PK Study of Diet Effect of Trazodone Hydrochloride Prolonged-Released Tablets in Healthy Chinese
A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
Worked on DESYREL at Pragma Bio? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
Working on DESYREL offers limited career growth given its LOE-approaching status and declining linked job openings; however, roles focus on defensively managing a mature asset through generic transition and optimizing profitability in niche segments. This is ideal for professionals seeking stable, operationally focused work rather than growth-stage innovation.